XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash $ 2,595,222 $ 4,203,488
Advances on research and development contract services 78,016
Prepaid insurance 22,558 17,116
Other prepaid expenses 49,824 10,000
Total current assets 2,667,604 4,308,620
Total assets 2,667,604 4,308,620
Current liabilities:    
Accounts payable and accrued expenses, including $0 and $36,250 to related parties at June 30, 2024 and December 31, 2023, respectively 131,404 156,758
Research and development contract liabilities, including $254,852 and $120,768 to related parties at June 30, 2024 and December 31, 2023, respectively 290,061 157,100
Total current liabilities 421,465 313,858
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares at June 30, 2024 and December 31, 2023 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares at June 30, 2024 and December 31, 2023 225 225
Additional paid-in capital 49,209,883 48,976,265
Accumulated deficit (50,463,969) (48,481,728)
Total stockholders’ equity 2,246,139 3,994,762
Total liabilities and stockholders’ equity $ 2,667,604 $ 4,308,620